Novartis Ag (NVS) Non-Current Deferred Tax Liability (2009 - 2026)

Novartis Ag has disclosed Non-Current Deferred Tax Liability across 12 years of filings, most recently posting -$2.5 billion for Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at -$2.5 billion, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.5 billion (changed N/A YoY), and the FY2025 annual result was $3.4 billion, up 525.16% from the prior year.
• Non-Current Deferred Tax Liability came in at -$2.5 billion for Q1 2026 at Novartis Ag, down from $3.4 billion in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.4 billion in Q4 2025 to a low of -$2.5 billion in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is -$163.0 million (2022), against an average of $601.6 million.
• Across the five-year window, Non-Current Deferred Tax Liability plunged 877.42% in 2022 and soared 933.66% in 2023, its largest moves.
• Novartis Ag's Non-Current Deferred Tax Liability stood at $2.7 billion in 2022, then plunged by 117.65% to -$474.0 million in 2023, then sank by 68.57% to -$799.0 million in 2024, then jumped by 525.16% to $3.4 billion in 2025, then slumped by 173.59% to -$2.5 billion in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at -$2.5 billion (Q1 2026), $3.4 billion (Q4 2025), and $2.3 billion (Q2 2025), per Business Quant data.